Ceftibuten: An overview

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 707-720

  Owens Jr , Robert C ^a,b   Nightingale, Charles H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b CHRISTIANA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTIBUTEN;

DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; ENZYME STABILITY; HUMAN; INFECTION; ORAL DRUG ADMINISTRATION; REVIEW;

ADULT; AGED; CEPHALOSPORINS; CHILD; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; OTITIS MEDIA; RESPIRATORY TRACT INFECTIONS;

EID: 1842301669     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Borga PC, Piatti G. Kinetics of filamentation of Escherichia coli induced by different subMICs of ceftibuten at different times. Chemotherapy 1993;39:272-7.
2. Wise R, Andrews JM, Ashby JP, Thornber D. Ceftibuten: in vitro activity against respiratory pathogens, β-lactamase stability, and mechanism of action. J Antimicrob Chemother 1990;26:209-13.
3. Debbia EA, Schito GC, Pesce A. Antibacterial activity of ceftibuten, a new oral third generation cephalosporin. J Chemother 1991;3:209-25.
4. Jones RN, Barry AL. Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, β-lactamase stability and broth microdilution quality control guidelines. Eur J Clin Microbiol Infect Dis 1988;7:802-7.
5. Jones RN, Barry AL. Antimicrobial activity, spectrum, and recommendations for disk diffusion susceptibility testing of ceftibuten (7432-S; SCH 39720), a new orally administered cephalosporin. Antimicrob Agents Chemother 1988;32:1576-82.
6. Thornsberry C. Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. Clin Infect Dis 1992;14(suppl 2):S189-94.
7. Kayser FH. In vitro activity of cefpodoxime in comparison with other oral beta-lactam antibiotics. Infection 1994;22(5):370-5.
8. Bauernfeind A. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany. Diagn Microbiol Infect Dis 1991;14:63-74.
9. Mazulli T, Simar AE, Jaeger R, et al. Comparative in vitro activities of several new fluoroquinolones and β-lactam antibiotics against community isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1990;34:467-9.
10. Doern GV. In vitro activity of ceftibuten against Haemophilus influenzas and Branhamella catarrhalis. Diagn Microbiol Infect Dis 1991;14:75-7.
11. Jones RN. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features. Pediatr Infect Dis J 1993;12:517-44.
12. Wise R, Andrews JM, Ashby JP, et al. Ceftibuten: a new orally absorbed cephalosporin Diagn Microbiol Infect Dis 1991;14:45-52.
13. Bauernfeind A. Ceftibuten and bacterial kinetics, comparative in vitro activity against Enterobacteriaceae producing extended spectrum β-lactamases. Diagn Microbiol Infect Dis 1991;14:89-92.
14. Bauernfeind A, Chong Y, Schweighart S. Extended broad spectrum β-lactamases in Klebsiella pneumoniae including resistance to cephamycins. Infection 1989;17:316-21.
15. Kitzis MD, Liassine N, Ferre B, et al. In vitro activities of 15 oral β-lactams against Klebsiella pneumoniae harboring new extended-spectrum β-lactamases. Antimicrob Agents Chemother 1990;34:1783-6.
16. Papanicolaou GA, Medeiros AA. Ability of ceftibuten to induce the class-1 β-lactamases of Enterobacter cloacae, Serratia marcescens, and Enterobacter aerogenes. Diagn Microbiol Infect Dis 1991;14:85-7.
17. Chin NX, Huang HB, Neu HC. Postantibiotic effect of ceftibuten on respiratory pathogens. Pediatr Infect Dis J 1995;14:S84-7.
18. Neu HC. Ceftibuten: minimal inhibitory concentrations, postantibiotic effect, beta-lactamase stability - a rationale for dosing programs. Pediatr Infect Dis J 1995;14:S88-92.
19. Bundtzen RW, Gerber AV, Cohn DL, Craig WA. Postantibiotic suppression of bacterial growth. Rev Infect Dis 1981;3:28-37.
20. Radwanski E, Teal M, Affrime M, et al. Multiple-dose pharmacokinetics of ceftibuten in healthy adults and geriatric volunteers. Am J Ther 1994;1:42-8.
21. Barr WH, Lin CC, Radwanski E, et al. The pharmacokinetics of ceftibuten in humans. Diagn Microbiol Infect Dis 1991;14:93-100.
22. Barr WH, Affrime M, Lin CC, Batra V. Pharmacokinetics of ceftibuten in children. Pediatr Infect Dis J 1995;14:S93-101.
23. Fassbender M, Lode H, Schaberg T, et al. Pharmacokinetics of new oral cephalosporins, including a new carbacephem. Clin Infect Dis 1993;16:646-53.
24. Lin C, Lim J, Radwanski E, et al. Pharmacokinetics and dose proportionality of ceftibuten in men. Antimicrob Agents Chemother 1995;39:359-61.
25. Sugawara M, Iseki K, Miyazaki K, et al. Transport characteristics of ceftibuten, cefixime, and cephalexin across human jejunal brush-border membrane. J Pharm Pharmacol 1991;43:882-4.
26. Schering Corp. Ceftibuten prescribing information. Kenilworth, NJ; 1995 Nov.
27. Nakashima M, Uematsu T, Takiguchi Y, et al. Phase I clinical studies of 7432-S, a new oral cephalosporin: safety and pharmacokinetics. J Clin Pharmacol 1988;28:246-52.
28. Lin C, Kumari P, Perrotta RJ, Reidenberg BE. Penetration of ceftibuten into middle ear fluid. Antimicrob Agents Chemother 1996;40:1394-6.
29. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255-9.
30. Scaglione F, Triscari F, Demartini G, Arcidiacono M, Cocuzza C, Fraschini F. Concentrations of ceftibuten in bronchial secretions. Chemotherapy 1995;41:229-33.
31. Kelloway JS, Awni WM, Lin CC, et al. Pharmacokinetics of ceftibuten cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency. Antimicrob Agents Chemother 1991;35:2267-74.
32. Wise R, O'Neill M, Nye P, et al. Pharmacokinetics and tissue penetration of ceftibuten. Antimicrob Agents Chemother 1990;34:1053-5.
33. Kearns GL, Reed MD, Jacobs RF, et al. Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children. Antimicrob Agents Chemother 1991;35:2078-84.
34. Ebert SC, Craig WA. Pharmacodynamic properties of antibiotics: application to drug monitoring and dosage regimen design. Infect Control Hosp Epidemiol 1990;11:319-26.
35. Nicolau DP, Quintiliani R, Nightingale CH. Antibiotic kinetics and dynamics for the clinician. Med Clin North Am 1995;79(3):477-95.
36. Nishida M, Murakawa T, Kamimura T, et al. Bactericidal activity of cephalosporins in an in-vitro model simulating serum levels. Antimicrob Agents Chemother 1994;38:1112-17.
37. McLinn SE, McCarty JM, Perrotta R, et al. Multicenter controlled trial comparing ceftibuten with amoxicillin/ clavulanate in the empiric treatment of acute otitis media. Pediatr Infect Dis J 1995;14:S108-14.
38. Bensch GW, Klaustermeyer WB, McCarty J, Schworer PB, Taglietti MA. Efficacy and safety of once-daily ceftibuten vs twice-daily ciprofloxacin in the treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin Pract 1995;4(suppl 2):S80-7.
39. Ziering W, McElvaine P, Taglietti M. Ceftibuten in the treatment of acute exacerbation of chronic bronchitis. Presented at 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17-20, 1995.
40. Hedrick J, Ripley P, Memon NA. Ceftibuten in the treatment of acute exacerbation of chronic bronchitis. Presented at 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15-18, 1996.
41. Perrotta R, McCabe R, Rumans L, et al. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of acute bacterial bronchitis. Infect Dis Clin Pract 1994;3:270-6.
42. McCabe R, Rumans L, Perrotta R, Mogabgab W. Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of pneumonia and bronchiectasis. J Chemother 1993;5:124-32.
43. Kammer RB, Ress R. Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections. Diagn Microbiol Infect Dis 1991;14:101-5.
44. Chirurgi VA, Edelstein H, Oster SE, et al. Ceftibuten versus cefaclor for the treatment of bronchitis. J Antimicrob Chemother 1991;28:577-80.
45. Galova K, Sufliarska S, Kukova Z, et al. Multicenter randomized study of two once daily regimens in the initial management of community-acquired respiratory tract infections in 163 children: azithromycin versus ceftibuten. Chemotherapy 1996;42:231-4.
46. Blumer JL, McLinn SE, De Abate CA, et al. Multinational multicenter controlled trial comparing ceftibuten with cefaclor for the treatment of acute otitis media. Pediatr Infect Dis J 1995;14:S115-20.
47. Goldstein FW, Acar JF, and the Alexander Project Collaborative Group. Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-93 Western Europe and USA collaborative surveillance study. J Antimicrob Chemother 1996;38(suppl A):71-84.
48. Brook I, Yocum P. Bacteriology and beta-lactamase activity in ear aspirates of acute otitis media that failed amoxicillin therapy. Pediatr Infect Dis J 1995;14(9):805-8.
49. Blumer JL, Forti WP, Summerhouse TL. Comparison of the efficacy and tolerability of once-daily ceftibuten and twice-daily cefprozil in the treatment of children with acute otitis media. Clin Ther 1996;18(5):811-20.
50. Mandel EM, Casselbrant ML, Kurs-Lasky M, Bluestone CD. Efficacy of ceftibuten compared with amoxicillin for otitis media with effusion in infants and children. Pediatr Infect Dis J 1996;1:409-14.
51. Pichichero ME, McLinn SE, Gooch WM, et al. Ceftibuten vs penicillin V in group A β-hemolytic streptococcal pharyngitis. Pediatr Infect Dis J 1995;14:S102-7.
52. Schering Corp. Data on file. Kenilworth, NJ; 1995.
53. Banfi A, Gabriele G, Hill-Juarez JM, et al. Multinational comparative trial of ceftibuten and trimethoprim-sulfamethoxazole in the treatment of children with complicated or recurrent urinary tract infections. Pediatr Infect Dis J 1993;12(suppl):S84-91.
54. Stein GE, Christensen S, Mummaw N. Treatment of acute uncomplicated urinary tract infection with ceftibuten. Infection 1991;19:124-6.
55. Reidenberg BE. Worldwide safety experience with ceftibuten pediatric suspension. Pediatr Infect Dis J 1995;14:S130-3.
56. De Abate CA, Perrotta RJ, Dennington ML, Ziering RM. The efficacy and safety of once-daily ceftibuten compared with coamoxiclav in the treatment of acute bacterial sinusitis. J Chemother 1992;4:358-63.
57. Nakashima M, Uematsu T, Takiguchi Y, et al. Phase I clinical studies of 7432-S: effect of 7432-S on platelet aggregation and blood coagulation. J Clin Pharmacol 1988;28:253-8.
58. Wiseman LR, Balfour JA. Ceftibuten: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1994;5:784-808.
59. Bachmann K, Schwartz J, Jauregui L, et al. Failure of ceftibuten to alter single dose theophylline clearance. J Clin Pharmacol 1990;30:444-8.
60. Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995;28:361-84.